IOTECH aspires to provide a forum for today's leaders in the field of #ImmunoOncology. We welcome: ➡️pre-clinical/clinical studies ➡️solid/haematological cancers ➡️technological advances that decipher & improve clinical outcomes Get in touch today!

🚨 SPECIAL ISSUE: Developments in Cell Therapy 🚨 ⏰ There's still time to consider submitting an original article or review - deadline 8 March 2024. 📈 ESMO IOTECH 2022 CiteScore: 5.5 Further details: spkl.io/60164sUYj Guest editors: Alena Gros & Sebastian Klobuch

The new EiCs of the ESMO Journals officially started their mandates this month. We look forward to witnessing the continued growth of the ESMO Journals under their guidance. 👏 Tom Powles G Curigliano MD PhD Rodrigo Dienstmann_MD_MBA Florian Lordick Prof. Irit Ben-Aharon John Haanen 👉ow.ly/k3kZ50Qusm5

IOTECH invites submissions for our Special Issue on Developments in Cell Therapy. Submission deadline: 8 March 2024. Find out more and submit your manuscript ➡️ spkl.io/60164sUYa ESMO IOTECH

✨SPECIAL ISSUE: Immunoengineering for cancer✨ 🔖Latest REVIEW now in print by Cui, Zhang Aarhus University & Yang Shi Uniklinik RWTH AC RWTH Aachen: Biomaterials-mediated ligation of immune cell surface receptors for immunoengineering Available #OpenAccess👇 esmoiotech.org/article/S2590-…

🔬Latest from Lavinia Spain and colleagues Updates in the pathogenesis and management of irAEs: enterocolitis, hepatitis and cardiovascular toxicities Available #OpenAccess 👇 esmoiotech.org/article/S2590-…

A masterclass in immune related adverse events from Lavinia Spain ESMO IOTECH

🚨 SPECIAL ISSUE: Developments in Cell Therapy 🚨 ⏰ Submit an original article/review by 1 July 2024 📈 2022 CiteScore: 5.5 🔖 Indexed on PMC & PubMed National Library of Medicine: 'Immunooncol Technol' Further details: spkl.io/60164sUYj Guest editors: Alena Gros & Sebastian Klobuch

Are you attending Keystone Symposia #KSCheckpoint24 on #CancerImmunotherapy in Whistler 🇨🇦 this week? Our Special Issue ‘Developments in Cell Therapy’ Editor - Alena Gros is here! Looking forward to discussing your work.

🧪 All you need to know about the state of play of cell therapy in solid cancers - Fantastic tour de force talk by Sebastian Klobuch AACR #AACR24 on advances in TILs & modified-TCR therapies. Also check out the latest review by Sebastian Klobuch & colleagues The Netherlands Cancer Institute 👇 nature.com/articles/s4157…

Are you attending AACR #AACR24 on in San Diego 🇺🇸 this week? Our Special Issue ‘Developments in Cell Therapy’ Editor - Sebastian Klobuch is here! Looking forward to discussing your work.

Congratulations Dr. Steven Rosenberg Surgery Branch National Cancer Institute for the #AACR24 AACR Award for Lifetime Achievement in Cancer Research 🏆!

First ESMO - Eur. Oncology Virtual Journal Club on May 22 at 630pm (CEST) - pencil down your agendas! Important data to be discussed by experts George Pentheroudakis FabriceAndre Solange Peters Andres Cervantes esmo.org/about-esmo-mee…

📢 Check out this latest original article Kyrillus Shohdy, MD & colleagues The Christie NHS Division of Cancer Sciences CRUK Manchester Institute East and North Hertfordshire NHS Trust AlexandriaUniversity. 🔬 Immune biomarker evaluation of sequential TKI & nivolumab monotherapies in RCC: Phase I TRIBE trial Available #OpenAccess👇 esmoiotech.org/article/S2590-…

📑 Presenting your work at #ASCO24 in Chicago 🇺🇸? Looking for a home for your research work? Consider submitting to ESMO IOTECH 👇 esmoiotech.org

📢 Check out this latest original article by Fernanda Costa Svedm & colleagues Karolinska Univ.sjuk @KarolinskaInst. 🏥 Effect of glucocorticoids for the management of irAEs on outcome in IO-treated melanoma patients. Available #OpenAccess👇 esmoiotech.org/article/S2590-…

📚 There's still time to submit your work to this ESMO IOTECH Special Issue on 'Developments in Cell Therapy', with guest editors: Alena Gros & Sebastian Klobuch. For further details, please check out: spkl.io/60164sUYj

Congratulations to our ESMO IOTECH's Editor-in-Chief John Haanen for the 2024 ESMO Lifetime Achievement Award 🏅. Well-deserved distinction, and we are all so delighted! #ESMO24 ESMO - Eur. Oncology

🔖 Latest REVIEW by Olivera & Ignacio Melero + colleagues on 'Regional and intratumoral adoptive T-cell therapy'. Available #OpenAccess 👇 esmoiotech.org/article/S2590-…

📢 Check out this latest original article by van Duin & colleagues - a multicentre study 🇳🇱. 🔬 Investigating association between TIL abundance in pre-tx primary/metastasis & development of severe irAEs in advanced melanoma. Available #OpenAccess 👇 esmoiotech.org/article/S2590-…